PT - JOURNAL ARTICLE AU - E Frans AU - R Dom AU - M Demedts TI - Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline AID - 10.1183/09031936.93.05020263 DP - 1992 Feb 01 TA - European Respiratory Journal PG - 263--265 VI - 5 IP - 2 4099 - http://erj.ersjournals.com/content/5/2/263.short 4100 - http://erj.ersjournals.com/content/5/2/263.full SO - Eur Respir J1992 Feb 01; 5 AB - A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy. These lesions even worsened for some weeks after interruption of cabergoline, which may possibly be related to the prolonged action of this drug. Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine.